Zobrazeno 1 - 10
of 164
pro vyhledávání: '"J, Speyer"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
E. Tarnowski, J-J Speyer
Publikováno v:
Aviation Safety ISBN: 9780429070372
Aviation Safety
Aviation Safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9856e6dd32710e18489a01b068b695d2
https://doi.org/10.1201/9780429070372-12
https://doi.org/10.1201/9780429070372-12
Autor:
M. Kwa, Judith D. Goldberg, Tsivia Hochman, S. Zamora, Yelena Novik, Sylvia Adams, M Meyers, R. Oratz, N. Klar, J. Speyer, Franco M. Muggia
Publikováno v:
Annals of Oncology. 31:S59
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d8d72660a4f25e5090c2c5b46e2e633
https://doi.org/10.1016/j.annonc.2020.03.232
https://doi.org/10.1016/j.annonc.2020.03.232
Autor:
James B. Hall, H. A. Burris, J. Speyer, J.D.A. Weber, Ursula A. Matulonis, Michael V. Seiden, Deborah K. Armstrong, Franco M. Muggia
Publikováno v:
Gynecologic Oncology. 104:727-731
Objective. The primary objective of this study was to determine the rate of response to matuzumab in patients with recurrent, EGFR-positive ovarian, or primary peritoneal cancer. Secondary end points included safety and tolerability, time to tumor pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f9a49cd776eb3da338e209913dbd652
https://doi.org/10.1016/j.ygyno.2006.10.019
https://doi.org/10.1016/j.ygyno.2006.10.019
Publikováno v:
2009 IEEE International Conference on IC Design and Technology.
A 30 volt, fully oxide isolated, complementary silicon bipolar technology with pnp cutoff frequencies greater than 3.5 GHz is presented in this paper. The process, developed within a fabless semiconductor company, provides high voltage, high speed an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bbd1abc4543741f91534e1c2274ffd0
https://doi.org/10.1109/icicdt.2009.5166261
https://doi.org/10.1109/icicdt.2009.5166261
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
H, Hochster, S, Wadler, C, Runowicz, L, Liebes, H, Cohen, R, Wallach, J, Sorich, B, Taubes, J, Speyer
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(8)
Twenty-one-day topotecan infusion was administered as second-line therapy in patients with previously treated ovarian cancer (based on our prior favorable phase I experience) to determine its activity, time to progression, and pharmacodynamics.Ovaria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::215205b7344e329d9aa036f53187b31d
https://pubmed.ncbi.nlm.nih.gov/10561322
https://pubmed.ncbi.nlm.nih.gov/10561322
Autor:
A, Fields, H, Hochster, C, Runowicz, J, Speyer, G, Goldberg, C, Cohen, P, Dottino, S, Wadler, G, Berk, H, Gretz, J, Mandeli, J, Holland, L, Letvak
Publikováno v:
Current opinion in oncology. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::22b67fb9ae91ced05175f31307408def
https://pubmed.ncbi.nlm.nih.gov/9988540
https://pubmed.ncbi.nlm.nih.gov/9988540
Autor:
J Wernz, Howard S. Hochster, M Meyers, J. Sanger, F. M. Muggia, E. Kramer, R. H. Blum, J. Speyer, A. Zeleniuch-Jacquotte, M. Rey, Michael D. Green
Publikováno v:
Cancer Treatment Reviews. 17:161-163
Doxorubicin is one of the most active drugs available for cancer chemotherapy. Its use is, however, often limited by the development of cumulative dose-related cardiomyopathy. The possibility ofinterfering with or preventing this toxicity in the clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0c9b6f3864b953ee917334b26b9d338
https://doi.org/10.1016/0305-7372(90)90041-d
https://doi.org/10.1016/0305-7372(90)90041-d
Autor:
J, Speyer, C, Wasserheit
Publikováno v:
Seminars in oncology. 25(5)
Anthracyclines are one of the most active classes of antineoplastic compounds. The limiting toxicity of this class of drugs is a cumulative, dose-related diffuse cardiomyopathy, which occurs in up to 20% of patients with a cumulative doxorubicin dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cc38fb3db94f280e92fb3a0c8726c884
https://pubmed.ncbi.nlm.nih.gov/9783592
https://pubmed.ncbi.nlm.nih.gov/9783592